MedTrace Logo

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

NCT00202579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-07-25

No results posted yet for this study

Summary

To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Ivabradine

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    lead OTHER

Principal Investigators

  • Luigi Tavazzi, Pr · Policlinico San Matteo

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202579 on ClinicalTrials.gov